HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Remains In US FDA Back Seat As Food, Tobacco Priorities Take Center Stage

Executive Summary

FDA Deputy Commissioner for Policy, Legislation and International Affairs Kimberlee Trzeciak has non-medical product work at top of her agenda, highlighting shift in attention that has been a mainstay of FDA commissioner Robert Califf's tenure.

You may also be interested in...

US FDA Gets Wanted Pathogen Program, Manufacturers Get Longer BARDA Contracts In Competing Pandemic Prep Bills

Key House and Senate committees advanced reauthorizations of the Pandemic All-Hazards Preparedness Act. It is unclear whether new perks for the FDA and drug makers will survive as the two chambers reconcile a myriad of differences between their plans. 

FDA – And Rx Supply Chain Resiliency – Strikeout In Senate’s Draft Pandemic Prep Bill

US FDA’s attempt to address drug shortage and supply chain weaknesses in the upcoming reauthorization of pandemic preparedness legislation looks unlikely as both chambers of Congress have now thrown wrenches in the plan.

Transparency Looms Large In US FDA’s Next-Pandemic Legislative Agenda

Agency’s proposals for pandemic preparedness reauthorization would build on CARES Act provisions to gain greater visibility into global pharmaceutical supply chains, while also seeking deeper understanding of manufacturing quality management activities. Also included in FY 2024 budget request: long-sought drug destruction and drug recall authorities.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts